Alpha Cognition is trading 7.3% down today at $8.16 as the stock enters a consolidation phase following a sharp run-up tied to its Alzheimer’s drug, Zunveyl.
- The downward move appears to be driven by profit-taking after recent significant gains, including an 8.6% surge on July 27.
- Recent upward momentum was supported by Zunveyl’s commercial launch progress and positive data from the BEACON real-world study.